The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer

被引：0
|
作者：
Nederby, Line
Raunkilde, Louise
Jakobsen, Anders
Jensen, Lars Henrik
Havelund, Birgitte Mayland
Wen, Sara Witting Christensen
Hansen, Torben
机构：
[1] Univ Hosp Southern Denmark, Inst Reg Hlth Res, Vejle Hosp, Dept Biochem & Immunol, Vejle, Denmark
[2] Univ Hosp Southern Denmark, Inst Reg Hlth Res, Vejle Hosp, Danish Colorectal Canc Ctr South, Vejle, Denmark
[3] Univ Hosp Southern Denmark, Inst Reg Hlth Res, Vejle Hosp, Dept Oncol, Vejle, Denmark
[4] Univ Hosp Southern Denmark, Vejle Hosp, Danish Colorectal Canc Ctr South, Vejle, Denmark
[5] Univ Hosp Southern Denmark, Vejle Hosp, Dept Oncol, Vejle, Denmark
[6] Univ Southern Denmark, Inst Reg Hlth Res, Danish Colorectal Canc Ctr South, Dept Oncol,Vejle Hosp, Vejle, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15514
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Irinotecan in the first-line treatment of colorectal cancer
    Saltz, LB
    ONCOLOGY-NEW YORK, 1998, 12 (08): : 54 - 58
  • [42] Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
    Shitara, K.
    Matsuo, K.
    Takahari, D.
    Yokota, T.
    Ura, T.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
    Shitara, Kohei
    Matsuo, Keitaro
    Takahari, Daisuke
    Yokota, Tomoya
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Ura, Takashi
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1757 - 1763
  • [44] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Thierry Landre
    Emilie Maillard
    Chérifa Taleb
    Djamel Ghebriou
    Gaetan Des Guetz
    Laurent Zelek
    Thomas Aparicio
    International Journal of Colorectal Disease, 2018, 33 : 1125 - 1130
  • [46] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Landre, Thierry
    Maillard, Emilie
    Taleb, Cherifa
    Ghebriou, Djamel
    Des Guetz, Gaetan
    Zelek, Laurent
    Aparicio, Thomas
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (08) : 1125 - 1130
  • [47] YEAR TO YEAR BUDGET IMPACT ANALYSIS OF BIOLOGICAL THERAPIES FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
    Martinez-Amores, B.
    Mezquita, L.
    Ibanez de Caceres, I.
    Ayuso, A.
    Pena, J. M.
    Perona, R.
    Grande, E.
    Belda-Iniesta, C.
    VALUE IN HEALTH, 2012, 15 (07) : A416 - A416
  • [48] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [49] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [50] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    British Journal of Cancer, 2011, 104 : 226 - 226
12345